

# Chronic Obstructive Pulmonary Disease (COPD) Drugs Market - 2024-2032

<https://marketpublishers.com/r/CA7B348D95D7EN.html>

Date: July 2025

Pages: 223

Price: US\$ 2,999.00 (Single User License)

ID: CA7B348D95D7EN

## Abstracts

The Chronic Obstructive Pulmonary Disease (COPD) Drugs Market was valued at US\$ 24.67 billion in 2024 and is anticipated to reach US\$ 35.15 billion by 2032, at a CAGR of 0.049 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Chronic Obstructive Pulmonary Disease (COPD) Drugs Market.

This report delivers a comprehensive overview of the Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Chronic Obstructive Pulmonary Disease (COPD) Drugs Market. The Chronic Obstructive Pulmonary Disease (COPD) Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2032.

Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Scope:

By Drug Class

Bronchodilators

Beclomethasone

Combination Inhaled Medicines

Phosphodiesterase Inhibitor (Roflumilast)

Antibiotics (Azithromycin)

Others

#### By Route of Administration

Inhalation

Oral

Others

#### By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

#### Key Players

Boehringer Ingelheim Pharmaceuticals, Inc.

Gsk Plc

Viartis Inc. (Mylan N.V.)

Lupin Pharmaceuticals, Inc.

Teva Pharmaceutical Industries Ltd.

AstraZeneca

Organon Group of companies

Pfizer Inc.

Covis Pharma GmbH

## Major Highlights

This report delivers a comprehensive overview of the Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Chronic Obstructive Pulmonary Disease (COPD) Drugs Market. The Chronic Obstructive Pulmonary Disease (COPD) Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2032.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

## Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

## Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

## Why Choose DataM?

**Data-Driven Insights:** Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

**Post-Purchase Support and Expert Analyst Consultations:** As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

**White Papers and Case Studies:** Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

**Annual Updates on Purchased Reports:** As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

**Specialized Focus on Emerging Markets:** DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than

offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

**Value of DataM Reports:** Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

### Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

## Contents

### **1. METHODOLOGY AND SCOPE**

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

### **2. DEFINITION AND OVERVIEW**

### **3. EXECUTIVE SUMMARY**

- 3.1. Snippet by Drug Class
- 3.2. Snippet by Route of Administration
- 3.3. Snippet by Distribution Channel
- 3.4. Snippet by Region

### **4. DYNAMICS**

- 4.1. Impacting Factors
  - 4.1.1. Drivers
    - 4.1.1.1. Increasing Prevalence of COPD
    - 4.1.1.2. XX
  - 4.1.2. Restraints
    - 4.1.2.1. Adverse Effects of Drugs
  - 4.1.3. Opportunity
  - 4.1.4. Impact Analysis

### **5. INDUSTRY ANALYSIS**

- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Patent Analysis
- 5.5. Regulatory Analysis
- 5.6. SWOT Analysis
- 5.7. Unmet Needs

### **6. BY DRUG CLASS**

## 6.1. Introduction

6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Drug Class

6.1.2. Market Attractiveness Index, By Drug Class

## 6.2. Bronchodilators\*

6.2.1. Introduction

6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

6.2.3. Anticholinergic Inhalers

6.2.4. Aclidinium

6.2.5. Glycopyrronium

6.2.6. Tiotropium

6.2.7. Umeclidinium

6.2.8. Revefenacin

6.2.9. Others

6.2.10. Beta-Agonist Inhalers

6.2.11. Arformoterol

6.2.12. Salmeterol

6.2.13. Olodaterol

6.2.14. Others

6.2.15. Inhaled Corticosteroids

## 6.3. Beclomethasone

6.3.1. Ciclesonide

6.3.2. Mometasone

6.3.3. Budesonide

6.3.4. Others

## 6.4. Combination Inhaled Medicines

6.4.1. Albuterol and Ipratropium

6.4.2. Budesonide and formoterol

6.4.3. Fluticasone and salmeterol

6.4.4. Fluticasone and vilanterol

6.4.5. Formoterol and mometasone

6.4.6. Others

## 6.5. Phosphodiesterase Inhibitor (Roflumilast)

## 6.6. Antibiotics (Azithromycin)

## 6.7. Others

# 7. BY ROUTE OF ADMINISTRATION

## 7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

## Administration

### 7.1.2. Market Attractiveness Index, By Route of Administration

## 7.2. Inhalation\*

### 7.2.1. Introduction

### 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

## 7.3. Oral

## 7.4. Others

## **8. BY DISTRIBUTION CHANNEL**

### 8.1. Introduction

#### 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

#### 8.1.2. Market Attractiveness Index, By Distribution Channel

### 8.2. Hospital Pharmacies\*

#### 8.2.1. Introduction

#### 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

### 8.3. Hospital Pharmacies

### 8.4. Retail Pharmacies

### 8.5. Online Pharmacies

## **9. BY REGION**

### 9.1. Introduction

#### 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

#### 9.1.2. Market Attractiveness Index, By Region

### 9.2. North America

#### 9.2.1. Introduction

#### 9.2.2. Key Region-Specific Dynamics

#### 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

#### 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

#### Administration

#### 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

#### 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

##### 9.2.6.1. U.S.

##### 9.2.6.2. Canada

##### 9.2.6.3. Mexico

### 9.3. Europe

#### 9.3.1. Introduction

#### 9.3.2. Key Region-Specific Dynamics

9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.3.6.1. Germany

9.3.6.2. U.K.

9.3.6.3. France

9.3.6.4. Spain

9.3.6.5. Italy

9.3.6.6. Rest of Europe

9.4. South America

9.4.1. Introduction

9.4.2. Key Region-Specific Dynamics

9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.4.6.1. Brazil

9.4.6.2. Argentina

9.4.6.3. Rest of South America

9.5. Asia-Pacific

9.5.1. Introduction

9.5.2. Key Region-Specific Dynamics

9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.5.6.1. China

9.5.6.2. India

9.5.6.3. Japan

9.5.6.4. South Korea

9.5.6.5. Rest of Asia-Pacific

9.6. Middle East and Africa

9.6.1. Introduction

9.6.2. Key Region-Specific Dynamics

9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

## **10. COMPETITIVE LANDSCAPE**

10.1. Competitive Scenario

10.2. Market Positioning/Share Analysis

10.3. Mergers and Acquisitions Analysis

## **11. COMPANY PROFILES**

11.1. Boehringer Ingelheim Pharmaceuticals, Inc.\*

11.1.1. Company Overview

11.1.2. Product Portfolio and Description

11.1.3. Financial Overview

11.1.4. Key Developments

11.2. Gsk Plc

11.3. Viatris Inc. (Mylan N.V.)

11.4. Lupin Pharmaceuticals, Inc.

11.5. Teva Pharmaceutical Industries Ltd.

11.6. AstraZeneca

11.7. Organon Group of companies

11.8. Pfizer Inc.

11.9. Covis Pharma GmbH (\*LIST NOT EXHAUSTIVE)

## **12. APPENDIX**

12.1. About Us and Services

12.2. Contact Us

## I would like to order

Product name: Chronic Obstructive Pulmonary Disease (COPD) Drugs Market - 2024-2032

Product link: <https://marketpublishers.com/r/CA7B348D95D7EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CA7B348D95D7EN.html>